Skip to content
Navigate to homepage - Cerba Research
Resource Library

Fact Sheet – Hematological Malignancies Trial Portfolio

Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Roundtable Report – Infectious Disease Clinical Trials: Navigating Innovation & Rising Complexity

COVID-19 accelerated infectious disease R&D, but timelines and funding are now normalizing. Persistent operational barriers remain, and improved surveillance and communication are needed to enhance vaccine development and trial efficiency.

Our roundtable report from the World Vaccine Congress 2024 discusses the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials.

Panelists

Nele Langenaken

General Manager, Cerba Research

Chijioke Bennett

Senior Director, Clinical Development, Novavax

Grace Chen

Vaccine Development Consultant

Trina Racine

Director, Vaccine Development, VIDO

John Rex

Chief Medical Officer, F2G

Roxana Rustomjee

Senior Director, Clinical Development, Infectious Diseases, BioNTech

Janelle Hart

Managing Editor, Custom Content, Citeline (Moderator)

Nele Langenaken – General Manager, Cerba Research

Chijioke Bennett – Senior Director, Clinical Development, Novavax

Grace Chen – Vaccine Development Consultant

Trina Racine – Director, Vaccine Development, VIDO

John Rex – Chief Medical Officer, F2G

Roxana Rustomjee – Senior Director, Clinical Development, Infectious Diseases, BioNTech

Janelle Hart – Managing Editor, Custom Content, Citeline (Moderator)

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us
Resource Library

Brochure – Highly Sensitive HPV Detection And Genotyping

Cerba Research offers specialized HPV diagnostic testing kits tailored to detect and identify HPV genotypes in vaccine and epidemiology studies. Take a look at our brochure and discover how our assay excels in analyzing HPV in formalin-fixed-paraffin embedded (FFPE) tissues, facilitating a correlation between histological findings and specific HPV genotypes.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us
Resource Library

Fact Sheet – Advancing Your Solid Tumor Trials With Our Cutting-Edge Assay Portfolio

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Unveiling the Oncology Journey: Highlighting Cutting-Edge Capabilities

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Virology Center of Excellence: Illuminating Insights Into Infectious Diseases

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Unlocking The Potential Of Rare Disease Drug Development

Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Case Study – Evidence For The Utility Of AI In Ki-67 Quantification In Solid Tumors

Although it is an important biomarker in oncology (mostly in breast and prostate), Ki-67 immunohistochemistry (IHC) analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability.

Digital analysis solutions to assist scoring with image analysis or artificial intelligence (AI) have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia Platform ® (AI platform) and Halo ® (image analysis supervised software) against three independent pathologists on various solid tumors.

Discover more about this in the case study.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and see how we can transform research and advance health together

Contact Us
Resource Library

White paper – Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

In the ever-evolving landscape of healthcare, Cell and Gene Therapy (CGT) stands at the forefront of groundbreaking advancements. With the power to precisely manipulate cells and genes for therapeutic purposes, CGT offers immense promise in treating diseases at their root.

In the whitepaper “Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio.”  we dive into the critical realm of patient safety within CGT. Authored by industry experts, this comprehensive guide presents a novel approach to patient safety monitoring, fusing breakthroughs in flow cytometry and genomics solutions.

Key Topics Covered:

🔍 Understanding the Risks: Ensuring Patient Safety: As CGT continues to revolutionize medicine, it’s imperative to acknowledge the inherent risks associated with these therapies. From the potential for insertional oncogenesis to the emergence of replication-competent viruses, safeguarding patient safety remains paramount.

📊 Key Capabilities: Vector Copy Number (VCN) Testing, Viral Integration Site (VIS) Analysis, Replication Competent Virus Testing, Immunophenotyping and Enumeration.

⚖️ FDA Concerns: FDA’s requirements to ensure safety and adverse events

And much more! Complete the form below to download the white paper now!

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Contact Us
Resource Library

Poster – Validation Of NanoString® Technologies For Solid Tumor Clinical Studies

Cerba Research Montpellier (CRM), a leader in histopathology and part of the Cerba Research group, is revolutionizing solid tumor clinical trials with our cutting-edge NanoString® platforms. Specializing in multiplex immunofluorescence for FFPE tissues, our lab now offers unparalleled transcriptomic and proteomic analysis capabilities.

Transforming Solid Tumor Clinical Trials with NanoString® Technology

Our recent acquisition of NanoString® technology enhances precision in solid tumor research. We have validated RNA analysis protocols for both bulk analysis using nCounter and spatial analysis with the GeoMx DSP platform’s whole transcriptome atlas (WTA). This advancement opens new doors in cancer research, extending potentially to other therapeutic areas.

Delve deeper into our innovative approach and its impact on solid tumor clinical trials by exploring our poster from SITC 2023. It showcases our advanced techniques and their applications in transformative cancer research.

NanoString’s nCounter Pro analysis system

Reach out to our experts and discover how we can transform research and advance health together

Contact Us